- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.05. | Passage BIO, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.04. | Passage BIO, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news | 1 | Investing.com | ||
| 21.04. | Regulatorischer Rückschlag: Oppenheimer halbiert Kursziel für Passage Bio | 3 | Investing.com Deutsch | ||
| 21.04. | Oppenheimer cuts Passage Bio stock price target on regulatory setback | 1 | Investing.com | ||
| 21.04. | Chardan downgrades Passage Bio stock rating on strategic review | 1 | Investing.com | ||
| 21.04. | Passage Bio: Chardan stuft Aktie nach strategischer Überprüfung auf 'Neutral' herab | 1 | Investing.com Deutsch | ||
| PASSAGE BIO Aktie jetzt für 0€ handeln | |||||
| 20.04. | Lucid downgrades Passage Bio stock rating on funding concerns | 19 | Investing.com | ||
| 20.04. | Why Is Passage Bio Stock Falling In Pre-market? | 15 | RTTNews | ||
| 20.04. | Passage Bio reports biomarker improvements in FTD trial | 2 | Investing.com | ||
| 20.04. | Passage Bio meldet positive Biomarker-Daten in Studie zu frontotemporaler Demenz | 3 | Investing.com Deutsch | ||
| 20.04. | Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates | 242 | GlobeNewswire (Europe) | PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent... ► Artikel lesen | |
| 20.04. | Passage BIO, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | Baird initiates Passage Bio stock coverage with outperform rating | 1 | Investing.com | ||
| 30.03. | Oppenheimer stuft Passage Bio mit "Outperform" ein und sieht massives Kurspotenzial | 2 | Investing.com Deutsch | ||
| 10.03. | Passage BIO, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.03. | Passage BIO, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 03.03. | Passage Bio GAAP EPS of -$4.09 | 1 | Seeking Alpha | ||
| 03.03. | Passage BIO, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.03. | Passage BIO, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,30 | +0,77 % | Tagesvorschau 15. Mai: Biontech-HV, BVB-Quartal, US-Industriedaten - das bringt der Freitag | Die turbulente Bilanzwoche klingt aus - doch der Freitag hält für Anleger noch einige spannende Termine bereit.Zum Wochenausklang dünnt der Terminkalender zwar aus, gewinnt aber spürbar an Schärfe.... ► Artikel lesen | |
| AMGEN | 290,00 | +1,68 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| NOVAVAX | 7,760 | -2,63 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 162,88 | +0,80 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | +4,14 % | Could Viking Therapeutics Be the Next Eli Lilly? | ||
| INTELLIA THERAPEUTICS | 10,640 | +0,95 % | Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? | ||
| TEMPUS AI | 39,900 | +1,09 % | How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here | ||
| BIOCRYST PHARMACEUTICALS | 7,370 | -2,02 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,590 | +7,95 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,760 | +0,14 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| EXELIXIS | 42,880 | -0,10 % | Merck inks Keytruda supply pact to support Exelixis' colorectal cancer trial | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,097 | +6,82 % | PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing | MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,126 | +0,36 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders | Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders... ► Artikel lesen | |
| ATAIBECKLEY | 3,700 | +5,71 % | Trump zündet den Turbo: Warum AtaiBeckley und Emyria jetzt im Fokus der Anleger stehen |
Das Unternehmen PASSAGE BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,36 % bei einem Aktienkurs von 5,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASSAGE BIO INC finden Sie auf Wallstreet Online.